Twitter Beğeni Hilesi

Great presentation by Martin Zarba discussing therapeutic options in pts with favorable and very favorable risk #mRCC from the #IMDC database! Daniel Heng Talal El Zarif, MD Eddy Saad Karl Semaan, MD, MSc ASCO @Oncoalert #ASCO24

Congratulations Rana McKay, MD, FASCO!

Please check out poster 280 by DrTylerStewart investigating NECTIN 4 RNA expression as potential biomarker in UC DrBagrodia Rana McKay, MD, FASCO UC San Diego Health Moores Cancer Center #ASCO24

Matched tissue and circulating tumor DNA analysis in #RenalCellCarcinoma #RCC: Results from a multimodal real-world database. Presentation by Rana McKay, MD, FASCO UC San Diego. #ASCO24 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/4aN0m4y ASCO

Brilliant work from Tom Powles et al in Nature Medicine.

Enfortumab vedotin with pembro vs chemo in previously untreated locally advanced or metastatic #UrothelialCarcinoma: analysis of cisplatin-eligible population from EV-302/KEYNOTE-A39. Presented by Jens Bedke. #ASCO24 written coverage by Julian Chavarriaga > bit.ly/3VpKjVT

Congratulations Dr. Sharon Choi (graduating fellow UC San Diego Health Moores Cancer Center) on her poster regarding disparate outcomes among Latino patients in mRCC. Dr. Choi is joining us this Fall! Rana McKay, MD, FASCO DrBagrodia Ithaar H. Derweesh Sumanta K. Pal, MD, FASCO #ASCO24

Perhaps the most important long-term bladder cancer data #ASCO24 Neoadjuvant Toripalimab & disitimab Vedotin in muscle invasive bladder cancer (n=47). pCR ⬆️ 63%. 14% G3/4 AEs. All surgeries occurred . The 1st MMAE/IO neoadjuvant combo data looks ✅✅. EV/IO MIBC trials awaited

Black 👩🏾 are underrepresented on trials & have some genomic differences. Therefore, our drugs developed may not be drugs that are better for them. I firmly believe we need better awareness & education around clinical trials BEFORE people are diagnosed with cancer. #ASCO24

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24 Designed by Amanda Myers

Final results of #CORE001 trial out now Nature Medicine (1/14) 35 pts with BCG-UR CIS treated w/ Creto + pembro 👉12mo CR (per RBB) = 57.1% (ITT) 👉24mo CR = 54% *(Auth Corr) 👉No patient progressed to MIBC 👉No synergistic toxicity Gary Steinberg nature.com/articles/s4159…

THRILLED to host the Testicular Cancer patient/caregiver meeting UC San Diego Health Moores Cancer Center in September! Indiana University Department of Urology Tim Masterson will give keynote! Please share with your patients...it's incredible! Sia Daneshmand, M.D. Scott Eggener Phillip Pierorazio nirm Nabil Adra UCSD Urology DM me for pamphlets!

The evolving role of radical cystectomy in the era of bladder-sparing therapies. Sima Porten UC San Francisco & Roger Li Moffitt Cancer Center join Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center in this discussion on the management of BCG-unresponsive #BladderCancer > bit.ly/45sFn64

congratulations to GW Urology #SarahAzari for matching UCSD Urology Society of Urologic Oncology Fellow for 2025-2027! We are delighted to welcome you to the UCSD Urology family! Ithaar H. Derweesh Manoj Monga DrBagrodia Amir Salmasi Juan Javier-DesLoges, MD, MS Michael Liss YUO Kit Yuen Yahir Santiago-Lastra | Urology

What a joy to see the overwhelming response to Alice Xiang and Karen joining our team here at CU Urology! Seems like we have a pair of all-star physicians coming our way.

When to stop PSA screening and how to say it. Very insightful talk from Scott Eggener at #CUA24

This week UCSD Urology : 2 open nephrectomies. Open rplnd. Robo rplnd. Robo ureteral recon with buccal graft. RALP. Partial penectomy. Plus all the minors. Join us, you will operate your face off ! UroResidency Jill C. Buckley Ithaar H. Derweesh Amir Salmasi DrBagrodia

Congratulations to Yu-Wei Chen, MD, MS, a 2024 recipient of the Robert A. Winn Diversity in Clinical Trials Career Development Award 🎉 Winn CDA supports the careers of early-stage investigators as they work to advance diversity in clinical trials. Learn More: bit.ly/4drEBc9

We've had no data on real-world EV+P use for mUC, until now. In European Urology we show rapid dissemination of EV+P in practice. As of 3/31/24, <4 mo after U.S. FDA full approval, EV+P accounted for ~50% of 1L tx starts, supplanting platinum-chemo (23%). authors.elsevier.com/a/1jeFg14kplyy…

UCSD Urology Resident Virtual Open House Tues, 9/17/2024 6-6:30p PDT via Zoom Register: ucsd.zoom.us/meeting/regist… Look for confirmation email with zoom details. Sponsored by UC San Diego Health Dept of Urology Yahir Santiago-Lastra | Urology UroResidency